Widely cited forecasts put the under-eye serum market at around $4.83 billion in 2025, growing past $11 billion by 2032. What’s interesting about that curve is where the volume is coming from: not the $90 department-store jar, but the sub-$20 tier that a decade ago would have been dismissed as a filler SKU.
That shift says more about how the category is manufactured now than about how it’s marketed.
Ten years of ingredient drift
The actives that anchored this category in the mid-2010s — peptides, retinol, hyaluronic acid, vitamin C, niacinamide — are all still in it. What changed is what got added around them, and why.
The same tolerance pressure is pushing some brands toward ingestible vitamin A formats as a topical alternative. Plant-derived actives came first. Bakuchiol arrived as the retinol substitute for tolerance-limited buyers, and madecassoside brought the barrier-repair story over from the cica category. Then came the biotech tier: growth factors, stem cell culture media, ingredients that carry a laboratory narrative rather than a botanical one. Both moves were partly commercial. A brand needs something to put on the front of a box, and the original five actives had long since stopped being differentiating.
Personalisation did the same work on the retail side. AR-based diagnostics and skin analysis apps let brands sell a routine rather than a bottle, and that reframing supported both higher basket sizes and higher trust — the recommendation feels earned rather than pushed. Ingredient transparency and published clinical data moved from optional to expected in roughly the same period.
Why the budget tier caught up
Most of the workhorse actives in this category came off patent, dropped in raw-material cost, or both. Hyaluronic acid, caffeine and standard peptide blends are no longer expensive inputs. A manufacturer can build a competent formula around them at a price point that supports a $20 retail — and that formula will do what it says: hydrate, reduce the look of puffiness, soften the appearance of fine lines.
What the budget tier still can’t easily buy is concentration of the expensive actives, stability testing at scale, elegant packaging, and clinical substantiation. Those are the four things a premium price is actually paying for, and only two of them are visible to the customer.
The practical consequence for buyers is that price is now a weak signal in this category. A $20 formula with caffeine and peptides and a $70 one with the same actives at similar levels will perform similarly on the puffiness and hydration side. The gap opens up on pigmentation-driven dark circles, where dose and delivery genuinely matter.
If you’re briefing this category
A few things follow for a brand developing an eye serum at any price point.
Pick one concern and dose for it. A brief asking for brightening, de-puffing, firming and hydration in one 15ml bottle produces a formula that under-delivers on all four, because every active has been diluted to make room for the others. Buyers who own an eye patch habit already understand that different products serve different jobs — they don’t need a single bottle to do everything.
Decide early whether the product is a serum or a cream in function, not just in name. The two overlap heavily in this category, and a thin, fast-absorbing formula that layers under something else is a different manufacturing problem than a standalone occlusive one.
Set the claim timeline against reality. Visible change around the orbital area is slow, and launch copy promising results in a fortnight generates returns at exactly the point where the formula was beginning to work.
And if you’re competing at $20, compete on texture and packaging rather than on ingredient count. The active list at that price is not going to be the differentiator, because everyone has access to the same raw materials. How the product feels, and whether the dropper works, is what gets it repurchased.
“Ten years is a useful frame because it shows how much buyer language has changed even when the underlying skin concerns — fine lines, puffiness, dark circles — haven’t. In client conversations today, brands rarely pitch an eye serum on ingredients alone; they want a personalization story, whether that’s a quiz, a diagnostic tool, or simply packaging that speaks to a specific concern. What we tell clients honestly is that budget-tier eye serums have gotten genuinely more credible in the last few years, so the marketing challenge for a $20 product is less about proving efficacy and more about earning trust against the assumption that cheap still means ineffective.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS